Microbiome Derived Nanomaterials for Improved Pulmonary Delivery: Recent Advancements and Future Prospects

The human microbiome, comprising a complex community of microorganisms, has emerged as a crucial factor in maintaining health and influencing disease states. Recently, there has been growing interest in harnessing the potential of microbiome-based nanomaterials for enhanced pulmonary drug delivery. This abstract presents an overview of recent advancements and prospects in this field. Microbiome-based nanomaterials offer a targeted and personalized approach to pulmonary delivery, leveraging an understanding of the lung microbiome. These nanomaterials can be engineered to encapsulate drugs or therapeutic agents, modulate the lung microbiome, act as diagnostic tools, regulate immune responses, and facilitate vaccine delivery. While significant progress has been made, challenges, such as formulation stability, safety, efficacy, and regulatory considerations, need to be addressed for successful translation into clinical practice. With continued research and technological advancements, microbiome-based nanomaterials hold great promise in revolutionizing pulmonary healthcare, providing novel strategies for the treatment and prevention of respiratory diseases.